Literature DB >> 34119622

Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy.

Shan Wang1, Jia-Lei Fu1, Hui-Feng Hao1, Yan-Na Jiao1, Ping-Ping Li2, Shu-Yan Han3.   

Abstract

Metabolic reprogramming, characterized by alterations of cellular metabolic patterns, is fundamentally important in supporting the malignant behaviors of cancer cells. It is considered as a promising therapeutic target against cancer. Traditional Chinese medicine (TCM) and its bioactive components have been used in cancer therapy for an extended period, and they are well-known for their multi-target pharmacological functions and fewer side effects. However, the detailed and advanced mechanisms underlying the anticancer activities of TCM remain obscure. In this review, we summarized the critical processes of cancer cell metabolic reprogramming, including glycolysis, mitochondrial oxidative phosphorylation, glutaminolysis, and fatty acid biosynthesis. Moreover, we systemically reviewed the regulatory effects of TCM and its bioactive ingredients on metabolic enzymes and/or signal pathways that may impede cancer progress. A total of 46 kinds of TCMs was reported to exert antitumor effects and/or act as chemosensitizers via regulating metabolic processes of cancer cells, and multiple targets and signaling pathways were revealed to contribute to the metabolic-modulating functions of TCM. In conclusion, TCM has its advantages in ameliorating cancer cell metabolic reprogramming by its poly-pharmacological actions. This review may shed some new light on the explicit recognition of the mechanisms of anticancer actions of TCM, leading to the development of natural antitumor drugs based on reshaping cancer cell metabolism.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Amino acid metabolism; Astragalus polysaccharide (PubChem CID: 2782115); Atractylenolide I (PubChem CID: 5321018); Berberine (PubChem CID: 2353); Brutieridin (PubChem CID: 101485561); Bufalin (PubChem CID: 9547215); Cancer cell metabolic reprogramming; Carnosic acid (PubChem CID: 65126); Celastrol (PubChem CID: 122724); Chlorogenic acid (PubChem CID: 1794427); Chrysin (PubChem CID: 5281607); DT-13 (PubChem CID: 101514160); Desmethoxycurcumin (PubChem CID: 5469424); Dioscin (PubChem CID: 119245); Emodin (PubChem CID: 3200); Euxanthone (PubChem CID: 5281631); Glycolysis; L42 (PubChem CID: 5288052); Licochalcone A (PubChem CID: 5318998); Lipid metabolism; MAP30 (PubChem CID: 451600); Matrine (PubChem CID: 91466); Melitidin (PubChem CID: 101485562); Melittin (PubChem CID: 16133648); Oleanolic acid (PubChem CID: 10494); Oridonin (PubChem CID: 5321010); Osthole (PubChem CID: 10228); Physapubescin I (PubChem CID: 132529929); Polyphyllin Ⅵ (PubChem CID: 10417550); Protopanaxadiol (PubChem CID: 9920281); Quercetin (PubChem CID: 5280343); Resibufogenin (PubChem CID: 6917974); Rhein (PubChem CID: 10168); Scutellarin (PubChem CID: 185617) Astragaloside IV (PubChem CID: 13943297); Shikonin (PubChem CID: 479503); Tanshinone IIA (PubChem CID: 164676); Tetrandrine (PubChem CID: 73708); Traditional Chinese medicine

Mesh:

Substances:

Year:  2021        PMID: 34119622     DOI: 10.1016/j.phrs.2021.105728

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  12 in total

1.  Trametes robiniophila Murr Sensitizes Gastric Cancer Cells to 5-Fluorouracil by Modulating Tumor Microenvironment.

Authors:  Jing-Li Xu; Li Yuan; Can Hu; Chun-Yan Weng; Han-Dong Xu; Yun-Fu Shi; Ling Huang; Jie-Er Ying; Zhi-Yuan Xu; Jiang-Jiang Qin; Xiang-Dong Cheng
Journal:  Front Pharmacol       Date:  2022-05-17       Impact factor: 5.988

Review 2.  Natural Bioactive Molecules: An Alternative Approach to the Treatment and Control of COVID-19.

Authors:  Fahadul Islam; Shabana Bibi; Atkia Farzana Khan Meem; Md Mohaimenul Islam; Md Saidur Rahaman; Sristy Bepary; Md Mizanur Rahman; Md Mominur Rahman; Amin Elzaki; Samih Kajoak; Hamid Osman; Mohamed ElSamani; Mayeen Uddin Khandaker; Abubakr M Idris; Talha Bin Emran
Journal:  Int J Mol Sci       Date:  2021-11-23       Impact factor: 5.923

3.  Licochalcone A suppresses Sp1 expression with potential anti-myeloma activity.

Authors:  Hua Bai; Min Zhou; He Zhou; Qiaoyan Han; Han Xu; Peipei Xu; Bing Chen
Journal:  Cancer Commun (Lond)       Date:  2021-10-19

4.  PKM2 Is the Target of a Multi-Herb-Combined Decoction During the Inhibition of Gastric Cancer Progression.

Authors:  Qingmin Sun; Mengyun Yuan; Hongxing Wang; Xingxing Zhang; Ruijuan Zhang; Haidan Wang; Xu Chen; Min Zhu; Shenlin Liu; Jian Wu
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

5.  Danggui Buxue Decoction Ameliorates Idiopathic Pulmonary Fibrosis through MicroRNA and Messenger RNA Regulatory Network.

Authors:  Huizhe Zhang; Xue Wang; Yanchen Shi; Mengying Liu; Qingqing Xia; Weilong Jiang; Yufeng Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-26       Impact factor: 2.650

Review 6.  Bioactive constituents of animal-derived traditional Chinese medicinal materials for breast cancer: opportunities and challenges.

Authors:  Chaochao Yu; Yi Li; Guopeng Chen; Chaoyan Wu; Xiuping Wang; Yingwen Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2022-07-15       Impact factor: 5.552

7.  Authentication of Shenqi Fuzheng Injection via UPLC-Coupled Ion Mobility-Mass Spectrometry and Chemometrics with Kendrick Mass Defect Filter Data Mining.

Authors:  Xingdong Wu; Yaowen Liu; Zijia Zhang; Zhihuang Ou; Guoxiang Wang; Tengqian Zhang; Huali Long; Min Lei; Liangfeng Liu; Wenhua Huang; Jinjun Hou; Wanying Wu; De-An Guo
Journal:  Molecules       Date:  2022-07-24       Impact factor: 4.927

8.  Study on the molecular mechanisms of tetrandrine against pulmonary fibrosis based on network pharmacology, molecular docking and experimental verification.

Authors:  Jie Li; Yi Wang; Rui Wang; Meng-Yu Wu; Jing Shan; Ying-Chi Zhang; Hai-Ming Xu
Journal:  Heliyon       Date:  2022-08-13

Review 9.  Targeting metabolic reprogramming in chronic lymphocytic leukemia.

Authors:  Yu Nie; Xiaoya Yun; Ya Zhang; Xin Wang
Journal:  Exp Hematol Oncol       Date:  2022-06-27

Review 10.  Recent Advances in Chinese Herbal Medicine for Cerebral Ischemic Reperfusion Injury.

Authors:  Ping Huang; Haitong Wan; Chongyu Shao; Chang Li; Ling Zhang; Yu He
Journal:  Front Pharmacol       Date:  2022-01-17       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.